Alaunos Therapeutics (TCRT)
(Delayed Data from NSDQ)
$1.81 USD
-0.05 (-2.69%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $1.83 +0.02 (1.10%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TCRT 1.81 -0.05(-2.69%)
Will TCRT be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for TCRT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRT
J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation
Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study
TCRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio
Alaunos (TCRT) Stock Sinks As Market Gains: What You Should Know
Other News for TCRT
Alaunos Therapeutics Announces Executive Financial Leadership Changes
Alaunos Therapeutics Regains Nasdaq Listing Compliance
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Q1 2023 Alaunos Therapeutics Inc Earnings Call Transcript
Alaunos Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript